PMID- 34481910 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20220531 IS - 1872-8227 (Electronic) IS - 0168-8227 (Linking) VI - 180 DP - 2021 Oct TI - Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study. PG - 109037 LID - S0168-8227(21)00396-X [pii] LID - 10.1016/j.diabres.2021.109037 [doi] AB - AIMS: The aim of this study was to compare the effectiveness of teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, at reducing a composite outcome of three metabolic risk factors (obesity, hypertension, and dyslipidemia) in Japanese patients with type 2 diabetes mellitus (T2DM) and metabolic risks. METHODS: In this prospective, multicenter, open-label, randomized, parallel-group comparison study, 162 patients with T2DM and one or more metabolic risk factors were randomized into a teneligliptin or canagliflozin group and treated for 24 weeks. The primary endpoint was the composite percentage of subjects who experienced an improvement in at least one metabolic risk after 24 weeks of treatment. RESULTS: The primary endpoint was achieved significantly by more patients in the canagliflozin group than in the teneligliptin group (62.2% vs. 31.3%, p = 0.0004). A >/= 3% body weight loss was also achieved by significantly more participants in the canagliflozin group than in the teneligliptin group (55.9% vs. 10.5%, p < 0.0001). CONCLUSIONS: This study showed canagliflozin to be more effective at reducing metabolic risks than teneligliptin. In Japanese patients with T2DM and metabolic risk factors, SGLT2 inhibitors may be superior to DPP-4 inhibitors at controlling multiple metabolic risk. CI - Copyright (c) 2021 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Son, Cheol AU - Son C AD - Division of Diabetes and Lipid Metabolism, National Cerebral and Cardiovascular Center, Suita, Japan. FAU - Makino, Hisashi AU - Makino H AD - Division of Diabetes and Lipid Metabolism, National Cerebral and Cardiovascular Center, Suita, Japan. FAU - Kasahara, Masato AU - Kasahara M AD - Nara Medical University Hospital, Kashihara, Japan. Electronic address: kasa@naramed-u.ac.jp. FAU - Tanaka, Tomohiro AU - Tanaka T AD - Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. FAU - Nishimura, Kunihiro AU - Nishimura K AD - Department of Preventive Medicine, National Cerebral and Cardiovascular Center, Suita, Japan. FAU - Taneda, S AU - Taneda S AD - Manda Memorial Hospital, Sapporo, Japan. FAU - Nishimura, Takeshi AU - Nishimura T AD - Takanohara Central Hospital, Nara, Japan. FAU - Kasama, Shu AU - Kasama S AD - Nara Medical University Hospital, Kashihara, Japan. FAU - Ogawa, Yoshihiro AU - Ogawa Y AD - Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. FAU - Miyamoto, Yoshihiro AU - Miyamoto Y AD - Open Innovation Center, National Cerebral and Cardiovascular Center, Suita, Japan. FAU - Hosoda, Kiminori AU - Hosoda K AD - Division of Diabetes and Lipid Metabolism, National Cerebral and Cardiovascular Center, Suita, Japan. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20210902 PL - Ireland TA - Diabetes Res Clin Pract JT - Diabetes research and clinical practice JID - 8508335 RN - 0 (Dipeptidyl-Peptidase IV Inhibitors) RN - 0 (Hypoglycemic Agents) RN - 0 (Thiazolidines) RN - 0SAC974Z85 (Canagliflozin) RN - 9NEZ333N27 (Sodium) RN - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Canagliflozin/therapeutic use MH - *Diabetes Mellitus, Type 2/drug therapy/epidemiology MH - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use MH - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use MH - Glucose/therapeutic use MH - Humans MH - Hypoglycemic Agents/therapeutic use MH - Japan/epidemiology MH - Prospective Studies MH - Risk Factors MH - Sodium/therapeutic use MH - Thiazolidines OTO - NOTNLM OT - Body weight loss OT - Hypertension OT - Lipid metabolism OT - Metabolic syndrome COIS- Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [CS received grants and personal fees from MSD, grants and personal fees, from Mitsubishi Tanabe Pharma Corporation, grants from Sanofi K.K., grants from Eli Lilly Japan K.K., grants from Novartis Pharma K.K., grants and personal fees from Takeda Pharmaceutical, personal fees from Taisho Toyama Pharmaceutical Co, personal fees from Fujifilm Pharma, and personal fees from Sumitomo Dainippon Pharma. MK received compensation as an advisor of the medical consulting firm Reason Why, Inc.; payments for lectures from Fuji Yakuhin, Pfizer, Daiichi Sankyo Co., Teijin, Fuji Film, Baxter, and Otsuka Pharmaceutical; and grants from Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., and Fuji Yakuhin. TT has stocks in Sumitomo Dainippon Pharma Co., Astellas Pharma Inc.; received payment for lectures from Taisho Toyama Pharmaceutical Co., Daiichi Sankyo Co., Mitsubishi Tanabe Pharma Corporation, AstraZeneca, EA Pharma Co., Kissei Pharmaceutical Co., Novartis Pharma, Takeda Pharmaceutical Co., Boehringer Ingelheim Japan, Kowa Pharmaceutical Co., MSD K.K., Astellas Pharma Inc., Ono Pharmaceutical Co., Amgen Astellas BioPharma K.K., Medtronic company, Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Co., Eli Lilly Japan K.K., the Japanese Society of Internal Medicine, Covidien Japan K.K., MMS Communications K.K. and Aichi Prefecture Insurance Medical Association; received honoraria for manuscript from Taisho Toyama Pharmaceutical Co., Nippon Rinsho Sha Co., Yodosha Co., Hokuryukan & NEW SCIENCE Co., SHINDAN TO CHIRYO SHA, Inc., and Kyoto University Press; and received grants from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Kamitsure Laboratory Co., Smoking Research Foundation, Japan Society for the Promotion of Science, Kowa Pharmaceutical Co., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co., Novo Nordisk Pharma, Taisho Toyama Pharmaceutical Co., Novartis Pharma, and Sanofi K.K. KN received grants from Philips Japan Co., Terumo Co., and Daiichi Sankyo Co. ST received payment for lectures from Novo Nordisk Pharma and Takeda Pharmaceutical. SK received grants from Mitsubishi Tanabe Pharma Corporation. YO received grants and personal fees from Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., and Astellas Pharma Inc., grants from AstraZeneca, Kyowa Hakko Kirin, Taisho Pharmaceutical, Mochida Pharmaceutical, Cosmic Co., Miyarisan Pharmaceutical, Kissei Pharmaceutical, Kowa Pharmaceutical, Roche DC Japan, Boehringer Ingelheim Japan, Novo Nordisk Pharma, Sanwa Kagaku Kenkyusho, Co., Sumitomo Dainippon Pharma, Sanofi K.K., Pfizer, Takeda Pharmaceutical. K.H. received grants, personal fees, and non-financial support from Mitsubishi Tanabe Pharma Co., personal fees from MSD, Sanofi, Eli Lilly, Novartis, Takeda, Astellas, Daiichi Sankyo, Amgen, Novo Nordisk Pharma, Kyowa Hakko Kirin, Ono, Sumitomo Dainippon, AstraZeneca, Taisho Pharma, Boehringer Ingelheim, and OMRON HEALTHCARE; grants from MSD, Sanofi, Eli Lilly, and Takeda. TN and YM declare no competing interests.]. EDAT- 2021/09/06 06:00 MHDA- 2021/11/25 06:00 CRDT- 2021/09/05 20:37 PHST- 2021/04/05 00:00 [received] PHST- 2021/08/27 00:00 [revised] PHST- 2021/08/31 00:00 [accepted] PHST- 2021/09/06 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2021/09/05 20:37 [entrez] AID - S0168-8227(21)00396-X [pii] AID - 10.1016/j.diabres.2021.109037 [doi] PST - ppublish SO - Diabetes Res Clin Pract. 2021 Oct;180:109037. doi: 10.1016/j.diabres.2021.109037. Epub 2021 Sep 2.